First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference35 articles.
1. First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials;Schuler;European Lung Cancer Congress (ELCC),2019
2. Characteristics of exceptional or super responders to cancer drugs;Prasad;Mayo Clin. Proc.,2015
3. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors;Hirsh;Ther. Adv. Med. Oncol.,2018
4. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?;Girard;Future Oncol.,2018
5. Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer;Song;Arch. Med. Sci.,2016
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Silencing of lncRNA LOC105376794 promotes migration, invasion, and gefitinib resistance of lung adenocarcinoma cells with EGFR 19del mutation by ATF4/CHOP axis and ERK phosphorylation;Neoplasma;2024
2. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations;Lung Cancer;2023-09
3. Next-generation sequencing-based detection in a breast MMPMN patient with EGFR T790M mutation: a rare case report and literature review;Frontiers in Oncology;2023-07-24
4. The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis;Disease Markers;2023-04-10
5. Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study;Therapeutic Advances in Medical Oncology;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3